{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:32:43Z","timestamp":1790775163825,"version":"4.1.0"},"reference-count":129,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T00:00:00Z","timestamp":1617926400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007048","name":"Mayo Foundation for Medical Education and Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:p>Paraneoplastic neurological syndromes are more commonly seen with malignancies such as small cell lung cancer, thymoma, gynecological malignancies, and breast cancer as well as seminoma. With the introduction of immune checkpoint inhibitor (ICI) cancer immunotherapy we see an increase of autoimmune neurological complications in patients with malignancies not traditionally associated with paraneoplastic neurological syndromes, such as melanoma and renal cell carcinoma. Immune checkpoint inhibitors enhance antitumor immune responses resulting often in immune-related adverse effects that can affect any organ, including the central and peripheral nervous system, neuromuscular junction and muscle. Neurological complications are rare; neuromuscular complications are more common than central nervous system ones but multifocal neurological presentations are often encountered. The vast majority of neurological complications appear within 3 months of ICI initiation, but have been described even after ICI cessation. Neural autoantibody testing reveals autoantibodies in approximately half of the patients with CNS complications. Early suspicion and diagnosis is critical to avoid worsening and improve outcomes. Therapeutic strategies depend on the severity of the symptoms and initially typically involve discontinuation of ICI and high dose steroids. Further immunosuppression might be necessary. Outcomes are dependent on patient's characteristics and clinical presentations.<\/jats:p>","DOI":"10.3389\/fneur.2021.642800","type":"journal-article","created":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T05:00:04Z","timestamp":1617944404000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":48,"title":["Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy"],"prefix":"10.3389","volume":"12","author":[{"given":"Cristina","family":"Valencia-Sanchez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia","family":"Zekeridou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJMoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B4","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3119","DOI":"10.1200\/JCO.2016.67.9761","article-title":"Safety and efficacy of durvalumab (MEDI4736), an anti-programmed cell death ligand-1 immune checkpoint inhibitor, in patients with advanced urothelial bladder cancer","volume":"34","author":"Massard","year":"2016","journal-title":"J Clin Oncol"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","article-title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma","volume":"376","author":"Bellmunt","year":"2017","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3851","DOI":"10.1200\/JCO.2016.72.1985","article-title":"Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study","volume":"35","author":"Hammers","year":"2017","journal-title":"J Clin Oncol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1093\/annonc\/mdx518","article-title":"Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study","volume":"28","author":"Necchi","year":"2017","journal-title":"Ann Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","article-title":"Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC","volume":"379","author":"Antonia","year":"2018","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-Line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","article-title":"PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma","volume":"379","author":"Migden","year":"2018","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1056\/NEJMoa1809615","article-title":"Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer","volume":"379","author":"Schmid","year":"2018","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.ejca.2018.11.020","article-title":"Long-term survival in patients with advanced non-small-cell lung cancer treated with atezolizumab versus docetaxel: results from the randomised phase III OAK study","volume":"107","author":"Von Pawel","year":"2019","journal-title":"Eur J Cancer."},{"key":"B20","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1093\/annonc\/mdt291","article-title":"Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)","volume":"24","author":"Mcdermott","year":"2013","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the society for immunotherapy of cancer (SITC) toxicity management working group","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.2147\/ITT.S141577","article-title":"Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events","volume":"6","author":"Davies","year":"2017","journal-title":"Immunotargets Ther"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2016.12.001","article-title":"Neurological adverse events associated with immune checkpoint inhibitors: review of the literature","volume":"73","author":"Cuzzubbo","year":"2017","journal-title":"Eur J Cancer."},{"key":"B24","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1093\/annonc\/mdw558","article-title":"Neurotoxicity from immune-checkpoint inhibition in the treatment of melanoma: a single centre experience and review of the literature","volume":"28","author":"Spain","year":"2017","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.ejca.2016.02.024","article-title":"Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy","volume":"60","author":"Zimmer","year":"2016","journal-title":"Eur J Cancer."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1001\/jamaneurol.2017.1912","article-title":"Neurological complications associated with anti-programmed death 1 (PD-1) antibodies","volume":"74","author":"Kao","year":"2017","journal-title":"JAMA Neurol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/ana.25708","article-title":"Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum","volume":"87","author":"Dubey","year":"2020","journal-title":"Ann Neurol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/s40425-019-0617-x","article-title":"Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study","volume":"7","author":"Johnson","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11060-019-03273-1","article-title":"Neurological and related adverse events in immune checkpoint inhibitors: a pharmacovigilance study from the japanese adverse drug event report database","volume":"145","author":"Sato","year":"2019","journal-title":"J Neurooncol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"e2442","DOI":"10.1212\/WNL.0000000000010632","article-title":"Neurological autoimmunity and immune checkpoint inhibitors: autoantibody profiles and outcomes","volume":"95","author":"Sechi","year":"2020","journal-title":"Neurology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1136\/jnnp-2020-323055","article-title":"Central nervous system complications associated with immune checkpoint inhibitors","volume":"91","author":"Vogrig","year":"2020","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1136\/jnnp.2003.034447","article-title":"Recommended diagnostic criteria for paraneoplastic neurological syndromes","volume":"75","author":"Graus","year":"2004","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"B33","doi-asserted-by":"publisher","first-page":"e604","DOI":"10.1212\/NXI.0000000000000604","article-title":"Increased frequency of anti-Ma2 encephalitis associated with immune checkpoint inhibitors","volume":"6","author":"Vogrig","year":"2019","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B34","volume-title":"Cellular and Molecular Immunology.","author":"Abbas","year":"2018"},{"key":"B35","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.jtho.2020.11.005","article-title":"Neurological complications of immune checkpoint inhibitors in thoracic malignancies","volume":"16","author":"Sechi","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","article-title":"Oncology meets immunology: the cancer-immunity cycle","volume":"39","author":"Chen","year":"2013","journal-title":"Immunity"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"B38","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B39","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune checkpoint blockade: a common denominator approach to cancer therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"B40","doi-asserted-by":"publisher","first-page":"1350","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B41","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","article-title":"Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion","volume":"8","author":"Dong","year":"2002","journal-title":"Nat Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"9543","DOI":"10.1128\/MCB.25.21.9543-9553.2005","article-title":"CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms","volume":"25","author":"Parry","year":"2005","journal-title":"Mol Cell Biol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nrneurol.2017.144","article-title":"Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives","volume":"13","author":"Yshii","year":"2017","journal-title":"Nat Rev Neurol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"2923","DOI":"10.1093\/brain\/aww225","article-title":"CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model","volume":"139","author":"Yshii","year":"2016","journal-title":"Brain"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e27384","DOI":"10.4161\/onci.27384","article-title":"Immunopathogenesis of paraneoplastic neurological syndromes associated with anti-Hu antibodies: a beneficial antitumor immune response going awry","volume":"2","author":"Pignolet","year":"2013","journal-title":"Oncoimmunology"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1038\/s41591-019-0523-2","article-title":"A case report of clonal EBV-like memory CD4(+) T cell activation in fatal checkpoint inhibitor-induced encephalitis","volume":"25","author":"Johnson","year":"2019","journal-title":"Nat Med"},{"key":"B47","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","article-title":"Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer","volume":"28","author":"Osorio","year":"2017","journal-title":"Ann Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1002\/ana.24715","article-title":"CTLA4 as immunological checkpoint in the development of multiple sclerosis","volume":"80","author":"Gerdes","year":"2016","journal-title":"Ann Neurol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"2290","DOI":"10.2353\/ajpath.2009.081012","article-title":"Accelerated course of experimental autoimmune encephalomyelitis in PD-1-deficient central nervous system myelin mutants","volume":"174","author":"Kroner","year":"2009","journal-title":"Am J Pathol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0165-5728(96)00168-3","article-title":"Specific blockade of CTLA-4\/B7 interactions results in exacerbated clinical and histologic disease in an actively-induced model of experimental allergic encephalomyelitis","volume":"73","author":"Hurwitz","year":"1997","journal-title":"J Neuroimmunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1212\/WNL.0000000000002594","article-title":"CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment","volume":"86","author":"Cao","year":"2016","journal-title":"Neurology"},{"key":"B52","doi-asserted-by":"publisher","first-page":"e001034","DOI":"10.1136\/jitc-2020-001034","article-title":"Reintroduction of immune-checkpoint inhibitors after immune-related meningitis: a case series of melanoma patients","volume":"8","author":"Cuzzubbo","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s11060-018-2752-5","article-title":"Neurologic complications of immune checkpoint inhibitors","volume":"137","author":"Fellner","year":"2018","journal-title":"J Neurooncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","article-title":"Management of immunotherapy-related toxicities, version 1","volume":"17","author":"Thompson","year":"2019","journal-title":"J Natl Compr Cancer Netw"},{"key":"B55","doi-asserted-by":"publisher","first-page":"e440","DOI":"10.1111\/jdv.15756","article-title":"Encephalitis induced by immune checkpoint inhibitors in metastatic melanoma: a monocentric retrospective study","volume":"33","author":"Galmiche","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1001\/jamaneurol.2016.1399","article-title":"Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer","volume":"73","author":"Williams","year":"2016","journal-title":"JAMA Neurol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"e597","DOI":"10.1016\/j.cllc.2018.04.009","article-title":"Nivolumab-induced limbic encephalitis with anti-hu antibody in a patient with advanced pleomorphic carcinoma of the lung","volume":"19","author":"Matsuoka","year":"2018","journal-title":"Clin Lung Cancer"},{"key":"B58","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1634\/theoncologist.2017-0344","article-title":"Anti-Hu-associated autoimmune limbic encephalitis in a patient with PD-1 inhibitor-responsive myxoid chondrosarcoma","volume":"23","author":"Papadopoulos","year":"2018","journal-title":"Oncologist"},{"key":"B59","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.jns.2015.01.028","article-title":"Anti-Ma-associated encephalomyeloradiculopathy in a patient with pleural mesothelioma","volume":"350","author":"Vogrig","year":"2015","journal-title":"J Neurol Sci"},{"key":"B60","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1136\/practneurol-2019-002464","article-title":"Autoimmune encephalitis associated with Ma2 antibodies and immune checkpoint inhibitor therapy","volume":"20","author":"Lyons","year":"2020","journal-title":"Pract Neurol"},{"key":"B61","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1186\/s13256-018-1786-9","article-title":"Nivolumab induced encephalopathy in a man with metastatic renal cell cancer: a case report","volume":"12","author":"Kopeck\u00fd","year":"2018","journal-title":"J Med Case Rep"},{"key":"B62","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1007\/s10072-018-3465-4","article-title":"Acute cerebellitis after administration of nivolumab and ipilimumab for small cell lung cancer","volume":"39","author":"Naito","year":"2018","journal-title":"Neurol Sci"},{"key":"B63","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.mayocpiqo.2017.12.001","article-title":"Association of immune-mediated cerebellitis with immune checkpoint inhibitor therapy","volume":"2","author":"Zurko","year":"2018","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"key":"B64","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1634\/theoncologist.2016-0366","article-title":"Case report: encephalitis, with brainstem involvement, following checkpoint inhibitor therapy in metastatic melanoma","volume":"22","author":"Bossart","year":"2017","journal-title":"Oncologist"},{"key":"B65","unstructured":"Phosphodiesterase 10A IgG: a novel biomarker of paraneoplastic neurologic autoimmunitye81522\n            ZekeridouA\n            KryzerT\n            GuoY\n            HassanA\n            LennonV\n            LucchinettiCF\n          10.1212\/WNL.000000000000797131315972Neurology932019"},{"key":"B66","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1200\/JCO.2011.38.7886","article-title":"Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma","volume":"30","author":"Maur","year":"2012","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1007\/s00415-018-8890-z","article-title":"Severe neurologic complications of immune checkpoint inhibitors: a single-center review","volume":"265","author":"Mancone","year":"2018","journal-title":"J Neurol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1002\/ccr3.2122","article-title":"Posterior reversible encephalopathy syndrome induced by nivolumab immunotherapy for non-small-cell lung cancer","volume":"7","author":"Kim","year":"2019","journal-title":"Clin Case Rep"},{"key":"B69","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/acn3.547","article-title":"Seronegative antibody-mediated neurology after immune checkpoint inhibitors","volume":"5","author":"Wilson","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1001\/jamaneurol.2019.4379","article-title":"CRMP5-IgG-associated paraneoplastic myelopathy with PD-L1 inhibitor therapy","volume":"77","author":"Kunchok","year":"2019","journal-title":"JAMA Neurol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1186\/s40425-019-0803-x","article-title":"Radiation myelitis after pembrolizumab administration, with favorable clinical evolution and safe rechallenge: a case report and review of the literature","volume":"7","author":"Carausu","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B72","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1177\/1352458514549403","article-title":"Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma","volume":"21","author":"Gettings","year":"2015","journal-title":"Mult Scler"},{"key":"B73","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1007\/s12094-019-02060-8","article-title":"Multiple sclerosis outcomes after cancer immunotherapy","volume":"21","author":"Garcia","year":"2019","journal-title":"Clin Transl Oncol"},{"key":"B74","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12885-018-3997-2","article-title":"Neuromyelitis optica spectrum disorder secondary to treatment with anti-PD-1 antibody nivolumab: the first report","volume":"18","author":"Narumi","year":"2018","journal-title":"BMC Cancer"},{"key":"B75","doi-asserted-by":"publisher","first-page":"102451","DOI":"10.1016\/j.msard.2020.102451","article-title":"Is neuromyelitis optica without AQP4-IgG a T-cell mediated disease? Insights from checkpoint inhibitor immune-related adverse events","volume":"46","author":"Nasralla","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"B76","doi-asserted-by":"publisher","first-page":"101447","DOI":"10.1016\/j.msard.2019.101447","article-title":"Neuromyelitis optica spectrum disorder after treatment with pembrolizumab","volume":"37","author":"Shimada","year":"2020","journal-title":"Mult Scler Relat Disord"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1097\/WNO.0000000000001148","article-title":"Neuro-Ophthalmic complications in patients treated with CTLA-4 and PD-1\/PD-L1 checkpoint blockade","author":"Sun","year":"2020","journal-title":"J Neuroophthalmol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1097\/CJI.0000000000000066","article-title":"Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma","volume":"38","author":"Crosson","year":"2015","journal-title":"J Immunother"},{"key":"B79","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ajo.2019.02.012","article-title":"Prevalence and clinical patterns of ocular complications associated with anti-PD-1\/PD-L1 anticancer immunotherapy","volume":"202","author":"Bitton","year":"2019","journal-title":"Am J Ophthalmol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1159\/000362614","article-title":"New-onset mediastinal and central nervous system sarcoidosis in a patient with metastatic melanoma undergoing CTLA4 monoclonal antibody treatment","volume":"37","author":"Murphy","year":"2014","journal-title":"Oncol Res Treat"},{"key":"B81","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1158\/2326-6066.CIR-15-0186","article-title":"Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma","volume":"4","author":"Khoja","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B82","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"key":"B83","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.lungcan.2017.05.002","article-title":"Recurrent dysphasia due to nivolumab-induced encephalopathy with presence of Hu autoantibody","volume":"109","author":"Raskin","year":"2017","journal-title":"Lung Cancer"},{"key":"B84","doi-asserted-by":"publisher","first-page":"e439","DOI":"10.1212\/NXI.0000000000000439","article-title":"Natalizumab may control immune checkpoint inhibitor-induced limbic encephalitis","volume":"5","author":"Hottinger","year":"2018","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"B85","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.gore.2018.03.007","article-title":"A case of severe encephalitis while on PD-1 immunotherapy for recurrent clear cell ovarian cancer","volume":"24","author":"Burke","year":"2018","journal-title":"Gynecol Oncol Rep"},{"key":"B86","doi-asserted-by":"publisher","first-page":"2548528","DOI":"10.1155\/2018\/2548528","article-title":"Nivolumab-Induced autoimmune encephalitis in two patients with lung adenocarcinoma","volume":"2018","author":"Shah","year":"2018","journal-title":"Case Rep Neurol Med"},{"key":"B87","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s00415-019-09666-6","article-title":"Immune checkpoint inhibitor induced anti-glutamic acid decarboxylase 65 (Anti-GAD 65) limbic encephalitis responsive to intravenous immunoglobulin and plasma exchange","volume":"267","author":"Chung","year":"2020","journal-title":"J Neurol"},{"key":"B88","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s40425-019-0727-5","article-title":"Unchecked immunity: a unique case of sequential immune-related adverse events with pembrolizumab","volume":"7","author":"Shah","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B89","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jneuroim.2016.12.016","article-title":"Autoimmune limbic encephalitis with anti-contactin-associated protein-like 2 antibody secondary to pembrolizumab therapy","volume":"305","author":"Brown","year":"2017","journal-title":"J Neuroimmunol"},{"key":"B90","doi-asserted-by":"publisher","first-page":"e1093","DOI":"10.1212\/WNL.0000000000008091","article-title":"Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies","volume":"93","author":"Dubey","year":"2019","journal-title":"Neurology"},{"key":"B91","doi-asserted-by":"publisher","first-page":"e866","DOI":"10.1212\/WNL.0000000000011340","article-title":"Cranial nerve disorders associated with immune checkpoint inhibitors","volume":"96","author":"Vogrig","year":"2020","journal-title":"Neurology"},{"key":"B92","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/jns.12371","article-title":"Incidence and characteristics of neurotoxicity in immune checkpoint inhibitors with focus on neuromuscular events: Experience beyond the clinical trials","volume":"25","author":"Bruna","year":"2020","journal-title":"J Peripher Nerv Syst"},{"key":"B93","doi-asserted-by":"publisher","first-page":"e229443","DOI":"10.1136\/bcr-2019-229443","article-title":"A rare case of Miller Fisher variant of Guillain-Barr\u00e9 Syndrome (GBS) induced by a checkpoint inhibitor","volume":"12","author":"Mcneill","year":"2019","journal-title":"BMJ Case Rep"},{"key":"B94","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1016\/j.clinph.2019.03.035","article-title":"Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy","volume":"130","author":"Chen","year":"2019","journal-title":"Clin Neurophysiol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"e000540","DOI":"10.1136\/esmoopen-2019-000540","article-title":"How we treat neurological toxicity from immune checkpoint inhibitors","volume":"4","author":"Spain","year":"2019","journal-title":"ESMO Open"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1212\/WNL.0000000000004359","article-title":"Nivolumab-related myasthenia gravis with myositis and myocarditis in Japan","volume":"89","author":"Suzuki","year":"2017","journal-title":"Neurology"},{"key":"B97","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1186\/s40425-019-0774-y","article-title":"Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature","volume":"7","author":"Safa","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B98","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1159\/000494078","article-title":"Lambert-eaton myasthenic syndrome caused by nivolumab in a patient with squamous cell lung cancer","volume":"10","author":"Nakatani","year":"2018","journal-title":"Case Rep Neurol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"5353202","DOI":"10.1155\/2019\/5353202","article-title":"Lambert-eaton myasthenic syndrome secondary to nivolumab and ipilimumab in a patient with small-cell lung cancer","volume":"2019","author":"Agrawal","year":"2019","journal-title":"Case Rep Neurol Med"},{"key":"B100","doi-asserted-by":"publisher","first-page":"fcaa181","DOI":"10.1093\/braincomms\/fcaa181","article-title":"Immune checkpoint inhibitor-associated myopathy: a clinicoseropathologically distinct myopathy","volume":"2","author":"Shelly","year":"2020","journal-title":"Brain Commun"},{"key":"B101","doi-asserted-by":"publisher","first-page":"e985","DOI":"10.1212\/WNL.0000000000006124","article-title":"Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer","volume":"91","author":"Touat","year":"2018","journal-title":"Neurology"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1002\/art.41604","article-title":"Inflammatory myositis in cancer patients receiving immune checkpoint inhibitors","author":"Aldrich","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","article-title":"Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: systematic review","volume":"92","author":"Johansen","year":"2019","journal-title":"Neurology"},{"key":"B104","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1161\/CIRCULATIONAHA.118.034497","article-title":"Myocarditis in the setting of cancer therapeutics: proposed case definitions for emerging clinical syndromes in cardio-oncology","volume":"140","author":"Bonaca","year":"2019","journal-title":"Circulation"},{"key":"B105","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1136\/annrheumdis-2018-213777","article-title":"Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1","volume":"78","author":"Mammen","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B106","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1056\/NEJMc1903064","article-title":"Alemtuzumab for immune-related myocarditis due to PD-1 therapy","volume":"380","author":"Esfahani","year":"2019","journal-title":"N Engl J Med"},{"key":"B107","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1056\/NEJMc1901677","article-title":"Abatacept for severe immune checkpoint inhibitor-associated myocarditis","volume":"380","author":"Salem","year":"2019","journal-title":"N Engl J Med"},{"key":"B108","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B109","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-19-3322","article-title":"Association of Anti-TNF with decreased survival in steroid refractory ipilimumab and Anti-PD1-Treated patients in the dutch melanoma treatment registry","volume":"26","author":"Verheijden","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B110","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","article-title":"Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer","volume":"36","author":"Arbour","year":"2018","journal-title":"J Clin Oncol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"3193","DOI":"10.1200\/JCO.2015.60.8448","article-title":"Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center","volume":"33","author":"Horvat","year":"2015","journal-title":"J Clin Oncol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"3807","DOI":"10.1200\/JCO.2017.73.2289","article-title":"Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III Trials","volume":"35","author":"Schadendorf","year":"2017","journal-title":"J Clin Oncol"},{"key":"B113","doi-asserted-by":"publisher","first-page":"750","DOI":"10.6004\/jnccn.2019.7310","article-title":"Preexisting autoimmune disease: implications for immune checkpoint inhibitor therapy in solid tumors","volume":"17","author":"Kennedy","year":"2019","journal-title":"J Natl Compr Canc Netw"},{"key":"B114","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/annonc\/mdx642","article-title":"Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma","volume":"29","author":"Pollack","year":"2018","journal-title":"Ann Oncol"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1158\/2326-6066.CIR-17-0755","article-title":"Safety and efficacy of re-treating with immunotherapy after immune-related adverse events in patients with NSCLC","volume":"6","author":"Santini","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B116","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1001\/jamaoncol.2019.1022","article-title":"Evaluation of readministration of immune checkpoint inhibitors after immune-related adverse events in patients with cancer","volume":"5","author":"Simonaggio","year":"2019","journal-title":"JAMA Oncol"},{"key":"B117","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1093\/annonc\/mdv623","article-title":"Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper","volume":"27","author":"Champiat","year":"2016","journal-title":"Ann Oncol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1001\/jamaoncol.2015.4368","article-title":"Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders","volume":"2","author":"Johnson","year":"2016","journal-title":"JAMA Oncol"},{"key":"B119","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1093\/annonc\/mdw443","article-title":"Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab","volume":"28","author":"Menzies","year":"2017","journal-title":"Ann Oncol"},{"key":"B120","doi-asserted-by":"publisher","first-page":"121","DOI":"10.7326\/M17-2073","article-title":"Use of immune checkpoint inhibitors in the treatment of patients with cancer and preexisting autoimmune disease: a systematic review","volume":"168","author":"Abdel-Wahab","year":"2018","journal-title":"Ann Intern Med"},{"key":"B121","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1200\/JCO.2017.77.0305","article-title":"Safety of programmed death-1 pathway inhibitors among patients with non-small-cell lung cancer and preexisting autoimmune disorders","volume":"36","author":"Leonardi","year":"2018","journal-title":"J Clin Oncol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1007\/s00262-019-02321-z","article-title":"Pre-existing autoimmune disease and the risk of immune-related adverse events among patients receiving checkpoint inhibitors for cancer","volume":"68","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B123","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1002\/acn3.51213","article-title":"HLA-B27 association of autoimmune encephalitis induced by PD-L1 inhibitor","volume":"7","author":"Chang","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1186\/s40425-019-0821-8","article-title":"Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study","volume":"7","author":"Manson","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B125","doi-asserted-by":"publisher","first-page":"576980","DOI":"10.1016\/j.jneuroim.2019.576980","article-title":"A case series of PD-1 inhibitor-associated paraneoplastic neurologic syndromes","volume":"334","author":"Gill","year":"2019","journal-title":"J Neuroimmunol"},{"key":"B126","doi-asserted-by":"publisher","first-page":"577184","DOI":"10.1016\/j.jneuroim.2020.577184","article-title":"Worsening of anti-Hu paraneoplastic neurological syndrome related to anti-PD-1 treatment: case report and review of literature","volume":"341","author":"Raibagkar","year":"2020","journal-title":"J Neuroimmunol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1001\/jamaneurol.2016.0603","article-title":"Frequency of synaptic autoantibody accompaniments and neurological manifestations of thymoma","volume":"73","author":"Zekeridou","year":"2016","journal-title":"JAMA Neurol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1111\/1759-7714.13009","article-title":"Paraneoplastic autoimmunity and small-cell lung cancer: Neurological and serological accompaniments","volume":"10","author":"Zekeridou","year":"2019","journal-title":"Thorac Cancer"},{"key":"B129","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.642800\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,9]],"date-time":"2021-04-09T05:00:08Z","timestamp":1617944408000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2021.642800\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,9]]},"references-count":129,"alternative-id":["10.3389\/fneur.2021.642800"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2021.642800","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,9]]},"article-number":"642800"}}